Cardiac Magnetic Resonance Imaging Guided Risk Stratification in Cardiac Sarcoidosis
心脏磁共振成像引导心脏结节病的风险分层
基本信息
- 批准号:10187288
- 负责人:
- 金额:$ 7.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-08-20 至 2023-07-31
- 项目状态:已结题
- 来源:
- 关键词:AccountingAdverse eventAffectAmericanArrhythmiaBiological MarkersBiopsyCardiacCardiac DeathCardiac SarcoidosisCardiovascular systemCessation of lifeCharacteristicsClinicalClinical ManagementCluster AnalysisDataDevicesDiagnosisDiseaseEtiologyEvaluationFinlandFundingGadoliniumGoalsGranulomatousHeart TransplantationHeart failureHistologicHospitalizationHospitalsImmunosuppressionImplantable DefibrillatorsInfectionInflammatoryLiteratureMagnetic Resonance ImagingMethodsMinnesotaMinorityMyocardialObservational StudyOutcomePathologyPatient-Focused OutcomesPatientsPharmaceutical PreparationsPhenotypePredispositionProspective StudiesQuality of lifeRegistriesResearchRiskSarcoidosisShockTestingToxic effectUniversitiesVentricular ArrhythmiaWorkadverse outcomebasecardiology serviceclinical Diagnosiscohortdemographicsheart damagehigh riskimage guidedimplantationimprovedleft ventricular assist devicemagnetic resonance imaging biomarkermortalitypatient stratificationpreventprognostic toolprognostic valueprospectiveracial diversityrandomized trialrisk stratificationside effectsudden cardiac death
项目摘要
PROJECT SUMMARY/ABSTRACT
An estimated 200,000 Americans live with sarcoidosis. Sarcoidosis is a multisystem granulomatous disease of
unknown etiology. Up to a quarter of patients with sarcoidosis may have cardiac involvement. Cardiac
sarcoidosis is the second leading cause of sarcoidosis-related mortality, accounting for up to a quarter of
deaths from sarcoidosis. Most deaths from cardiac sarcoidosis are due to ventricular arrhythmias.
Cardiovascular magnetic resonance imaging is frequently used in the evaluation of patients with suspected or
known cardiac sarcoidosis. In this proposal, we aim to investigate cardiovascular magnetic resonance imaging
biomarkers that may be associated with adverse outcomes in patients with suspected or known cardiac
sarcoidosis. Using this information, we will identify integrative phenotypes – composed of biomarkers from
cardiovascular magnetic resonance imaging, demographics, and clinical characteristics – associated with
adverse cardiac outcomes. The proposed work will establish high- and low-risk phenotypes of cardiac
sarcoidosis patients that predict benefit from immunosuppression and/or implantable cardioverter-defibrillators
to prevent sudden arrhythmic cardiac death and other cardiac sarcoidosis-related adverse outcomes. These
data will lay the groundwork for prospective studies testing the strategy of using the integrative phenotypes to
select cardiac sarcoidosis patients for treatments. Selective and appropriate use of these treatments could
improve long-term clinical outcomes in patients with cardiac sarcoidosis, in particular by preventing ventricular
arrhythmia-related sudden cardiac death.
项目摘要/摘要
据估计,美国有20万人患有结节病。结节病是一种多系统肉芽肿性疾病。
病因不明。多达四分之一的结节病患者可能有心脏受累。心脏
结节病是与结节病相关的死亡的第二大原因,占多达四分之一
死于结节病。大多数心脏结节病的死亡是由于室性心律失常。
心血管磁共振成像经常用于评估疑似或
已知心脏结节病。在这项提案中,我们的目标是研究心血管磁共振成像
可能与可疑或已知心脏病患者不良结局相关的生物标志物
结节病。利用这些信息,我们将识别整合的表型--由来自
心血管磁共振成像、人口学和临床特征-与
心脏方面的不良后果。拟议的工作将建立心脏病的高风险和低风险表型。
预测从免疫抑制和/或植入型心脏复律除颤器获益的结节病患者
预防心律失常猝死和其他心脏结节病相关不良结局。这些
数据将为测试使用整合表型的策略的前瞻性研究奠定基础
选择心脏结节病患者进行治疗。有选择地和适当地使用这些治疗方法可以
改善心脏结节病患者的长期临床结果,特别是通过预防脑室结节病
与心律失常相关的心脏性猝死。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Chetan N Shenoy其他文献
Chetan N Shenoy的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Chetan N Shenoy', 18)}}的其他基金
Cardiac Magnetic Resonance Imaging Guided Risk Stratification in Cardiac Sarcoidosis
心脏磁共振成像引导心脏结节病的风险分层
- 批准号:
10472465 - 财政年份:2021
- 资助金额:
$ 7.75万 - 项目类别:
Cardiac Fibrosis and Risk Prediction in Cancer Treatment-Related Cardiotoxicity
心脏纤维化和癌症治疗相关心脏毒性的风险预测
- 批准号:
9087970 - 财政年份:2016
- 资助金额:
$ 7.75万 - 项目类别:
Cardiac Fibrosis and Risk Prediction in Cancer Treatment-Related Cardiotoxicity
心脏纤维化和癌症治疗相关心脏毒性的风险预测
- 批准号:
9924641 - 财政年份:2016
- 资助金额:
$ 7.75万 - 项目类别:
相似海外基金
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10707830 - 财政年份:2023
- 资助金额:
$ 7.75万 - 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
- 批准号:
479728 - 财政年份:2023
- 资助金额:
$ 7.75万 - 项目类别:
Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
- 批准号:
10884567 - 财政年份:2023
- 资助金额:
$ 7.75万 - 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
- 批准号:
10751964 - 财政年份:2023
- 资助金额:
$ 7.75万 - 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
- 批准号:
486321 - 财政年份:2022
- 资助金额:
$ 7.75万 - 项目类别:
Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10676786 - 财政年份:2022
- 资助金额:
$ 7.75万 - 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10440970 - 财政年份:2022
- 资助金额:
$ 7.75万 - 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
- 批准号:
10642998 - 财政年份:2022
- 资助金额:
$ 7.75万 - 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10482465 - 财政年份:2022
- 资助金额:
$ 7.75万 - 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
- 批准号:
10191053 - 财政年份:2020
- 资助金额:
$ 7.75万 - 项目类别: